Solid Biosciences (SLDB) Asset Utilization Ratio (2022 - 2023)
Solid Biosciences' (SLDB) quarterly Asset Utilization Ratio came in at 0.03 in Q2 2023, down 4.2% year-on-year from 0.03 in Q2 2022, and up 2.4% quarter-over-quarter from 0.03 in Q4 2022.
Solid Biosciences (SLDB) Asset Utilization Ratio (2022 - 2023) Analysis & Trends
Solid Biosciences has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.03 for Q2 2023.
- Asset Utilization Ratio for Q2 2023 came in at 0.03, down 4.2% year-over-year; the trailing twelve-month figure through Jun 2023 was 0.03 (down 4.2% YoY), and the FY2022 annual result was 0.03, down 51.32% from the prior year.
- Asset Utilization Ratio came in at 0.03 for Q2 2023 at Solid Biosciences, up from 0.03 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.03 in Q3 2022 to a low of 0.03 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 0.55 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Solid Biosciences | 789.54 Mn | 408.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 0.03 |
| Dec 31, 2022 | 0.03 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.03 |